Dr. Subrahmanyam Pitchika is a pharmaceutical scientist with strong expertise in Formulation Research & Development (FRD), nanotechnology-based drug delivery systems (NDDS), and technical application support. He is currently serving as Assistant Manager – Technical Support at Arihant Innochem Pvt. Ltd., India (Dec 2023–Present), where he contributes to business development, formulation R&D (solids), regulatory coordination, and project management.
Earlier, he completed his industrial M.Pharm research internship at Aurobindo Pharma Limited, Hyderabad, successfully executing a project on Formulation and Evaluation of Lopinavir and Ritonavir Tablets using Hot Melt Extrusion Technology, demonstrating early proficiency in advanced formulation technologies. He also holds a Post Graduate Diploma in Computer Applications (PGDCA) with First Class with Distinction, strengthening his technical skill set towards computer science.

Research Interests & Core Expertise

Dr. Pitchika’s research interests span pharmaceutical nanotechnology, cancer drug delivery, oral and transdermal delivery systems, liposomes, nanoparticles, bilosomes, and 3D printing in drug development. His multidisciplinary expertise bridges basic pharmaceutical sciences and translational research, with applications in oncology, hypertension, vaccines, and poorly soluble drugs.

Research Publications

He has authored multiple high-quality research and review articles in reputed international journals, focusing on:

• Nanocarrier-based cancer therapeutics targeting multidrug resistance

• Liposomal and polymeric nanoparticle systems for enhanced efficacy

• Advances in 3D printing in drug development

• Trans-ungual and transdermal drug delivery strategies

• In-vivo and pharmacokinetic evaluation of nanoformulations

Notably, his works published in journals such as Journal of Drug Delivery Science and Technology, Letters in Applied NanoBioScience, and Journal of Applied Pharmaceutical Science highlight his consistent and impactful research contributions.

Patents & Innovations

Dr. Pitchika is an inventor/co-inventor of multiple Indian patent applications, primarily in cancer immunotherapy and pharmaceutical nanotechnology, including:

• Cancer immunotherapy based on nano-medicines

• Pharmaceutical nanotechnology for intravenous administration

• Multifunctional composite nanomaterial drug carrier systems

These patents underscore his innovative mindset and commitment to developing next-generation drug delivery solutions.

Revenue Impact of Approved Research & Development Projects

Dr. Subrahmanyam Pitchika’s research and development contributions have translated into successful USFDA-approved and prequalified pharmaceutical products, resulting in substantial commercial value and sustained revenue generation for leading global pharmaceutical companies. His involvement in formulation development, technical execution, and regulatory-aligned R&D has directly supported the commercialization of multiple high-value therapeutics across cardiovascular, oncology, antiviral, and metabolic disease segments.

The following approved products represent few market-launched formulations with established global demand, contributing to recurring revenues through regulated markets such as the United States and WHO-prequalified supply chains:

• Alembic Pharmaceuticals – Final USFDA Approval for Dexlansoprazole Delayed-Release Capsule whose estimated market size is $285 million for twelve months ending september 2025 according to IQVIA

• Alembic Pharmaceuticals – USFDA Tentative Approval for Selexipag tablets 0.2 mg, 0.4 mg,0.6 mg,0.8 mg,1.4 mg,1.6 mg

• Aurobindo Pharma – USFDA Approval for Valsartan Tablets

• Alembic Pharmaceuticals – USFDA Tentative Approval for Palbociclib Capsules (75 mg, 100 mg, 125 mg)

• Aurobindo Pharma – USFDA Approval for Amlodipine and Valsartan Tablets

• Aurobindo Pharma – Final USFDA Approval for Metformin Hydrochloride Extended-Release Tablets

• Aurobindo Pharma – USFDA Approval for Apixaban Tablets (2.5 mg and 5 mg)

• Azurity Pharmaceuticals, Inc. – FDA Approval of DANZITENT™ (Nilotinib) Tablets, the first and only nilotinib formulation without mealtime restrictions

• Shanghai Desano – WHO Prequalification of Ritonavir Tablets

• Desano – WHO Prequalification of Atazanavir/Ritonavir Fixed-Dose Combination Tablets

Collectively, these approvals represent high-value regulated products with sustained lifecycle revenues driven by chronic-use indications, oncology therapeutics, and global public health programs. Dr. Pitchika’s R&D contributions demonstrate a clear linkage between scientific innovation, regulatory success, and commercial revenue realization, underscoring his strength in translational and industry-impact research.

This measurable revenue impact further strengthens his eligibility for the “Best Researcher of the Year” award by evidencing not only academic excellence but also economic, industrial, and societal value creation.

Honors, Awards & Recognitions

• Lifetime Achievement Award (2022) by the International Research Awards on Oncology and Cancer Research, presented at the 12th Edition Oncology Summit, for contributions to nanotechnology in breast cancer therapy.

• IESRF Young Researcher Award (2023) by the Innovative Education and Scientific Research Foundation, recognizing his emerging leadership and scientific excellence.

Eligibility for Best Researcher of the Year

Dr. Subrahmanyam Pitchika is highly eligible for the “Best Researcher of the Year” award under Scientific Laurels due to his consistent publication record, patented innovations, international recognition, and translational research impact, particularly in pharmaceutical nanotechnology and oncology. His ability to integrate academic research with industrial application, along with prestigious awards and patents, clearly demonstrates research excellence, originality, and societal relevance, fulfilling the core criteria for this distinguished honor.